Agendia brings new personalized treatment for breast cancer patients
 

Agendia, a world leader in molecular cancer diagnostics, today announced that its breast cancer product offering, consisting of breast cancer recurrence test MammaPrint(R), and TargetPrint(TM), has been expanded with BluePrint (TM) to report important additional information on tumor subtypes.

More...